Cholesterol Hope, PTV News: Mar 18, 2010




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Cholesterol Hope, PTV News: Mar 18, 2010
Released on: March 18, 2010. © PharmaVentures Ltd
Visitors: You are watching a 1 minute preview.
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
Genzyme and Isis announce positive phase III trials for inherited high LDL drug
Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.
Nigel Borshell
Senior Advisor
PharmaVentures

Nigel has over 30 years experience in Life Sciences including senior international commercial management roles in diagnostics and biotechnology gained at drug testing specialists Syva Company, Hoechst’s Behring division, US diagnostics giant Dade Behring, and as European Business Development Director for California-based Cepheid. Nigel is the author of numerous Pharmaceutical/Biotech Industry reports, papers and articles. At PharmaVentures, Nigel specialises in valuation methodologies, deal structure modelling, and pricing policies.
Isis Pharmaceuticals
The biotechnology company is developing drug therapies based on antisense technology, in which drugs attach themselves to strands of RNA in order to prevent them from producing disease-causing proteins; the hoped-for end result is a therapy that fights disease without harming healthy cells. Isis Pharmaceuticals works by discovering potential compounds (primarily in the areas of cardiovascular and metabolic disease but also in a range of other categories) and finding larger pharmaceutical partners to license the drugs or collaborate in their development.
Genzyme
Genzyme Corporation is a biotechnology company based in Cambridge, Massachusetts. Genzyme is the world’s third-largest biotechnology company, employing more than 11,000 people around the world. The company has a presence in approximately 40 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories, its products are sold in 90 countries.
PharmaVentures Ltd
PharmaVentures is a company that has proven success in deals and alliances.

PharmaVentures offers:


• Over 18 years of healthcare industry experience

• Experience gained from working with in excess of 1000 clients in 38 countries, and conducting more than 450 assignments

• Over 40 specialist advisors, analysts and researchers

• Skills honed in many countries - 80% of its business comes from outside the UK